Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts)
Michael E. Stokes(Ithaka Harbors), Norah J. Shire(AstraZeneca (United States)), Jill Walker(AstraZeneca (United Kingdom)), Helen K. Angell(Délégation Paris 5), Craig Barker(AstraZeneca (United Kingdom)), Maria Secrier(University College London), Marlon C. Rebelatto(AstraZeneca (Japan)), Sophie Wildsmith(AstraZeneca (United Kingdom)), Paul Scorer(Centro de Pesquisas Oncológicas), R. Wang
Cited by 6
Related Papers
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
|Immunity|2016|1.1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
|Science Translational Medicine|2016|474